NHS Winter Update

Alberto Costa Excerpts

Monday 8th January 2024 Commons Chamber

[Victoria Atkins]

I reassure the hon. Lady that the impact of mental health patients remaining in A&E for any length of time, let alone beyond 72 hours, is genuinely a metric and factor that we look at very carefully, as we have done throughout the strikes. We appreciate that A&E is not the right environment for most people who are suffering from a mental health illness or a psychotic episode, and we want to move them into appropriate care as quickly and safely as we can. With that in mind, I hope that she will welcome the fact that we are spending some £7 million for up to 100 mental health ambulances over the next two years, to try to ensure that people get the right care they need, when they need it. More than 160 projects are being allocated funding in the community, including crisis cafés and safe havens, so that hopefully people are caught before the crisis happens and they end up in A&E.

[Alberto Costa (South Leicestershire) (Con)]

I welcome the winter update from the Secretary of State. There is actually a winter update going on in South Leicestershire. Will she join local NHS stakeholders there, and me, in encouraging South Leicestershire’s constituents to respond to the consultation on the future of the Feilding Palmer Hospital? The deadline is 14 January.

[Victoria Atkins]

I would be happy to do so. I am pleased to hear of local NHS leaders actively seeking the views of the patients and communities they serve, in order to ensure that their services are what the public expect from their local hospitals, and from primary and secondary care services.

Government Contracts: Randox Laboratories

Alberto Costa Excerpts

Thursday 10th February 2022 Commons Chamber

[Maggie Throup]

I make no apologies for how we as a country rose to the challenge that we faced in early 2020. I think that sometimes we forget what this country—indeed, the world—was going through. We must remember those days, and I am sure that hon. Members across the House will agree that what we have put in place since will ensure that we can cope far better in the future. We do need to learn lessons, and we will learn lessons.

However, one of the most important lessons that I take from when we worked together is that we can do incredible things. The NHS has been phenomenal, our hospitals have been phenomenal, and local government has been phenomenal, as has the private sector. We have all worked together and we have really worked hard, and that is why we can now see that—with the vaccine programme as well, along with the therapeutics and antivirals—we are combating this virus. We could not have come this far without everybody working together, and this country’s testing structure has been crucial in helping us to get through this time. I would like to take this opportunity to thank everybody who has been involved in this huge effort both at testing sites and working in the lab, and everybody who has come forward to get tested to keep their loved ones safe.

I would like to respond to some of the questions posed by the hon. Lady. My Department did inform you, Mr Speaker, that we were unable to meet our initial deadline for responding to the Humble Address. That was mainly due to the surge of omicron at that time, and the way that my Department had to respond to ensure that we kept our citizens safe from that variant surge.

The hon. Lady raised the issue of the Randox kits that were recalled in the summer of 2020. It was on 15 July that year that NHS Test and Trace was notified that some kits produced by Randox laboratories may not have met the required standard for coronavirus testing. As a precautionary measure, while this was investigated further, NHS Test and Trace paused the use of these Randox test kits with immediate effect. It was on 7 August that the Medicines and Healthcare Products Regulatory Agency instructed Randox to recall the Randox covid-19 home testing kits with a specific catalogue number. That decision was taken as a precautionary measure to prevent any further use of these Randox tests. The risk to safety was low, and test results from Randox kits were not affected. An independent assessment in June 2020 had placed Randox ahead of other laboratories, and Randox was meeting its delivery targets by September 2020. We were very precautionary in the measures we put in place to ensure that we were protecting everybody at that time.

I did note the point of order that the hon Lady made this week about the meeting on 9 April 2020, which she has raised again today. The note was taken during the meeting, and it was saved in a draft folder of the private secretary who took the note. When the Department received a freedom of information request for the minute of the meeting, the private secretary found the minute and shared it. For clarity, “note” and “minute” mean an official record of a meeting; the words mean the same from that point of view.

I reiterate that there are robust rules and processes in place that ensure that contracts are awarded in accordance with the public procurement regulations of 2015, and that Ministers are not involved in the assessment and evaluation process for contracts at all. That is a really important principle that the Government work on now, and have worked on probably for decades, and that principle will never be broken.

[Alberto Costa (South Leicestershire) (Con)]

You will remember, Mr Speaker, as the right hon. Member for Chorley, and every Member in this House will remember, the enormous pressure we were all put under, barely two years ago, to try to find businesses and organisations that could quickly produce much-needed equipment and services to assist the people of our country during an unprecedented global pandemic. Can I put on record my appreciation of the enormous work that the Government did, and does the Minister agree with me that, had it not been for their work, we would not have been able to protect and save the lives of so many people in our country?

[Maggie Throup]

I appreciate my hon. Friend’s recognition, remembering where we were barely two years ago, of how we have moved on since then. We have put in place a test and trace programme that is renowned across Europe and across the world, and we have a world-leading vaccination programme as well as the amazing work done on therapeutics and antivirals. Coming together in the national effort has been vital, which is why I make no apologies for my Department’s looking at every opportunity to ensure that everybody could get tested who needed to be tested, that everybody could be jabbed who needed to be jabbed, and that the right therapeutics were in place to keep people safe.

Medical Cannabis under Prescription: Children with Epilepsy

Alberto Costa Excerpts

Wednesday 3rd November 2021 Westminster Hall

[Alberto Costa (South Leicestershire) (Con)]

I beg to move,

That this House has considered medical cannabis under prescription for children with epilepsy.

It is a pleasure to serve under your chairmanship, Ms Bardell, and I am very grateful to open this debate on an issue that affects many of our constituents. I do not propose to speak for long, because I can see that quite a large number of colleagues are in the Chamber and would like to speak as well. If they have not already done so, I invite them to inform the Chair that they wish to speak.

I wish to mention my constituents Maya, who is nine years old, and Evelina, who is just four. Maya and Evelina suffer from rare forms of epilepsy and rely on medical cannabis to improve their quality of life. Their families are currently having to pay up to £2,000 a month for private prescriptions of medical cannabis, as they are unable to access that medicine on the NHS. Their families are also having to go to unbelievable lengths to raise money, something that has been made more difficult during the pandemic as there has been less opportunity to fundraise. Maya’s family have set up a Facebook page called “Mercy for Maya”, where her mum Samantha runs monthly fundraisers and raffles to help with the enormous monthly costs. My constituents should not have to do this for something that is legal on the NHS.

[Christine Jardine (Edinburgh West) (LD)]

The picture that the hon. Member paints is one that I and many other hon. Members are familiar with, because we also have constituents going through the same ridiculous hoops to get a legally available medicine. Is he aware of any other medication in this country for which that has ever been the case—it has been legal and available, but people have had to raise the money for it themselves in this way?

[Alberto Costa]

I am not sure, but I doubt that our constituents would have to put their hands in their pockets to the tune of £2,000 a month to pay for any other medication that was extremely important for their severely ill children. My constituents, and indeed all Members’ constituents who have children in this situation, should not have to pay for this medication themselves.

Medical cannabis has had lots of benefits for Maya, including preventing her from having prolonged seizures, which has meant less time in hospital. Medical cannabis has also improved her alertness and engagement. She used to spend a lot of time asleep during the day, but she is now able to attend school, which she very much enjoys.

Both I and colleagues have lobbied the Government tirelessly to widen access to this life-changing and life-saving treatment. I am sure that I speak for many Members here today in expressing delight that medical cannabis was made legal in specialist cases in November 2018. This week marks three years since that law change.

I welcome the new Minister to her place and the good progress that the Government have made on widening access to medical cannabis. I am also grateful to her for agreeing to meet me, as co-chair of the all-party parliamentary group for access to medical cannabis under prescription, along with my colleague the hon. Member for Gower (Tonia Antoniazzi), later this month. I look forward to discussing the issues in greater detail with her.

You may be interested to learn, Ms Bardell, that since the very welcome law change three years ago, which should have improved the lives of children who suffer with rare and intractable forms of epilepsy, only three prescriptions have been issued on the NHS—only three prescriptions. At this point, I would like to clarify that we are talking about whole-plant extract. This type of medical cannabis, containing CBD and THC—cannabidiol and tetrahydrocannabinol—together with many other active ingredients, has been life transforming for a small cohort of families and their children. It is vital that that point is understood, as there have been several hundred prescriptions for a fully licensed paediatric drug known as Epidiolex, but that is primarily CBD-only. There is an acknowledgement that that drug has a role to play, but it was not the subject of the appeals that were so eloquently and passionately made by the families concerned when they visited Parliament at the start of this week.

Access to medical cannabis was legalised after high-profile campaigning by me and other Members across the House, who are here today, and the hard work of the group End Our Pain. It and other campaigners, along with some of my colleagues, worked with the then six-year-old Alfie Dingley, who also suffers from rare, intractable epilepsy, to help him secure access to medical cannabis. In 2018, after intensive campaigning, Alfie was granted the first ever long-term licence for the type of medical cannabis that is life transforming. Medical cannabis subsequently became legalised in specialist cases on 1 November 2018. Since Alfie secured the prescription, his transformation has been significant. He has gone from suffering up to 150 life-threatening seizures a day to recently celebrating being 500 days seizure free. The change in health and quality of life for Alfie is nothing short of transformative, and that transformation has been evident in many others, too.

I am very grateful to the Secretary of State for Health and Social Care, who in 2018 was the Home Secretary who granted the licence for medical cannabis to Alfie Dingley. I know that my right hon. Friend cares deeply about this issue. Now that he is Secretary of State for Health, I urge him to consider the recommendations that I am mentioning today on what further action could be taken to help children like my constituents to access medical cannabis on the NHS. The law change has been a change in legislation, but not in practice. That has been reflected in the number of NHS prescriptions that have been issued. My constituents and many others were greatly reassured by the steps that this Government took to legalise these treatments in 2018, but they are understandably dismayed that actions have not followed words in this case.

There are a few reasons for this blockage on NHS prescriptions. At the same time that the law changed, a number of bodies issued guidance on how and when medical cannabis should be prescribed. Those bodies included the British Paediatric Neurology Association, the General Medical Council, the National Institute for Health and Care Excellence and the Royal College of Physicians, but let us be clear: nothing—absolutely nothing—in any of the guidance states that it is wrong or not allowed to prescribe this medicine, either privately or on the NHS.

However, I am advised by the families and advocates on this issue that the guidance paints a somewhat confusing picture. In my capacity as co-chair of the APPG, I have attended a number of meetings with senior NHS leaders. In those meetings, they tell me that if an NHS consultant wishes to prescribe medical cannabis, they are able to do so. The British Paediatric Neurology Association does not currently support the use of whole-plant medicinal cannabis, which includes the THC ingredient, and has published guidance stating that only neurologists should be allowed to prescribe cannabinoids containing CBD. That guidance has been criticised for being overly restrictive.

The high level of caution in the guidance issued is likely to have played its part in preventing the prescribing of those products and making NHS trusts unwilling to provide funding. Currently, there are only three paediatricians in Britain who prescribe the whole-plant oil to children with drug-resistant epilepsy, and one of them is to retire imminently, meaning that families are at risk of losing their prescriptions.

A few months ago we had a breakthrough, as NICE issued clarification of its guidance relating to the use of medical cannabis for drug-resistant paediatric epilepsy. It has now made it clear that clinicians can prescribe medicinal cannabis in appropriate cases. However, even since the clarification of the guidance, the hesitancy among the medical profession remains.

I am aware that this issue continues to receive a high degree of media, public and political attention, and I am concerned that some of those involved—perhaps some of the medical professional bodies such as the BPNA—may be experiencing a temptation to entrench and dig in. If that is the case, I make a plea to them and their medical professional colleagues to reject that temptation and instead to reach out to work with the Department of Health and Social Care, the Minister and her colleagues, the families and interested politicians to find a way forward to help these vulnerable families and their children.

I also strongly encourage the Government to ensure better education for paediatric neurologists on whole-plant extract medical cannabis and its benefits for children with drug-resistant epilepsy. I am aware that the previous Secretary of State for Health and Social Care tasked the NHS with undertaking a review of the blockage on NHS prescriptions. The review reported in August 2019 and made two main recommendations: first, that an expert panel be set up to advise on the prescription of medical cannabis in cases of paediatric epilepsy; and secondly, that a trial should be set up to inform the evidence base on safety and efficacy, and to act as a way of getting these families access to the medicine for free.

The families and campaigners have told me that those recommendations offered them great hope and a way forward. However, things have not worked out as the families hoped. Yes, the expert panel was set up; it is called RESCAS—the refractory epilepsy specialist clinical advisory service—and its members are indeed experts in paediatric epilepsy, but as far as the families can see they are not experts in the way that whole-plant extract has worked both here in the UK and overseas.

Imagine, then, the enormous disappointment when one of the very first cases considered was turned down for medical cannabis. The young boy in question is experiencing a life transformation similar in positive impact to that which Alfie is experiencing. The panel is not working. I know the Minister cares deeply about this matter. I hope she will agree that the make-up and terms of the panel are in need of urgent review so that it includes expertise not just in the condition itself, but in the medicine too.

The other main recommendation of the August 2019 review was the establishment of trials. I understand that the Government’s position is that there needs to be more research in the area before prescriptions can be available more freely. The proposed trial was to be observational, which meant the children could continue on the medicine and their condition be evaluated by medical professionals. It soon became clear last year that plans for the observational trial had been dropped and replaced with a randomised control trial. RCTs are not appropriate in this case, as I am sure hon. Members agree, as they require some of the cohort to be taken off the medicine and given a placebo.

That is simply not possible, and we have to ask ourselves why anyone would take their children off a medicine that was already working for them and improving their quality of life. RCTs can also be incredibly costly and take years to complete. That is time that my constituents and others do not have. I therefore suggest that the Government consider conducting an observational trial or an alternative study as a means of enabling the children to have continued access to medical cannabis at no cost. That would be possible for the Secretary of State, and the Under-Secretary of State for Health and Social Care, my hon. Friend the Member for Lewes (Maria Caulfield), here today, to commission under the National Health Service Act 2006.

[Tahir Ali (Birmingham, Hall Green) (Lab)]

The cost of having medicinal cannabis for children is astronomical, at between £800 and £2,000, and that is for those who can afford it. The very children who need the medicine to improve the quality of their lives where it has been proven to be effective and who cannot afford it cannot be put on the scrapheap to further delay. Does the hon. Gentleman agree?

--- Later in debate ---

[Alberto Costa]

I think it is imperative that we work cross party and we encourage, cajole and push the Government to do the right thing. The right thing is what? While acknowledging that the Ministers have these powers, I understand that there are concerns about whether such action might lead to unintended consequences in the form of legal challenge relating to other drugs. I am a lawyer; I understand that. I used to work in government and defend the Government from judicial review. I understand.

However, I believe that any such concerns and risks could be mitigated. I also suggest in the meantime that the Government use the discretionary fund that they have at their disposal to cover the cost of the private prescriptions. There are a small number of children and families across the country in this desperate financial situation. The Government can intervene financially to reduce the burden every month, so that families such as my constituents Maya and Evelina do not have to rely on the uncertainty of fundraising. That is my favoured option, and I urge my hon. Friend the Minister to access that fund.

During the pandemic, Maya had to be rushed to A&E a few times due to her condition. Surely these children needing to go to hospital to have urgent medical treatment is more costly to the NHS than providing them with the prescription they need. Therefore, I suggest, only as an interim measure—I plead—that the Government consider covering the costs of the private prescriptions for the most vulnerable children in our country suffering from severe epilepsy who need this medication, until the Government find a solution with the bodies and particularly the medical profession.

In conclusion, I urge my colleagues in Government to consider the recommendations that I and other colleagues across the House have made and are making here today, as well as listening to the families affected. While I appreciate the good work that the Government have done on this issue, they can and should go further. I and many colleagues across the House will continue to champion this matter: better access to medicinal cannabis on the NHS for my constituents, all the constituents affected across our country and all the children suffering from this awful illness, so that they get the drugs necessary, free at the point of need on the NHS.

[Hannah Bardell (in the Chair)]

Before I call speakers, I want to acknowledge those who are with us in the Chamber today and those who are watching. I also acknowledge the importance of this subject. Because it is such an important subject and I want to call the Front Bench by 5.34 pm, with the Labour and Scottish National party spokespersons having five minutes each, I will impose an initial time limit of four minutes to ensure that every Member has the opportunity to represent this very important issue.

--- Later in debate ---

[Alberto Costa]

I thank all Members for contributing this evening. I thank the Minister for her response. Clearly, it is not the response that I was hoping for, but I know that she genuinely wants to find a solution.

I have offered a temporary solution. Doctors are prescribing this medication, but they are prescribing it privately. Many private prescriptions are being given by the medical profession to kids such as Evelina and Maya. My request once again to the Minister in my summing up is about her having a discretionary fund. Why do I know that? Because her predecessor told me so in answer to one of the debates that we had. The Minister has that discretionary fund and the executive authority to permit private prescriptions—which the parents of Evelina and Maya, and all the other parents across the country, have to pay for—to come from that pot, as a temporary solution until the Government, the regulatory bodies, the medicinal bodies and the medical profession sort out the issue.

I will be coming back to the Minister, I am afraid, once again requesting access to that fund.

Question put and agreed to.

Resolved,

That this House has considered medical cannabis under prescription for children with epilepsy.

Medicinal Cannabis

Alberto Costa Excerpts

Monday 6th September 2021 Commons Chamber

[Alberto Costa (South Leicestershire) (Con)]

I congratulate the hon. Lady on securing this debate. I am co-chair of the all-party parliamentary group for access to medical cannabis under prescription, having taken over from my right hon. Friend the Member for Hemel Hempstead (Sir Mike Penning). One of my constituents, Maya, is nine years old and has a rare form of epilepsy. Her family are having to pay up to £2,000 a month for medical cannabis, despite the revisions of the guidance. I thank the Minister, my hon. Friend the Member for Bury St Edmunds (Jo Churchill), who is in her place, for the good work she has already done, and I am very grateful for the correspondence that she and I have exchanged, but does the hon. Member for Edinburgh West (Christine Jardine) agree that the Government can do much more, particularly on liaising with clinical commissioning groups to get this medicinal cannabis to the children who need it?

[Christine Jardine]

I thank the hon. Member for making an excellent point. The APPG has done astonishing work over the past few years in support of this, but yes, the Government could do so much more for those families who know what it is like to get to the end of every month, and of every prescription, and face the huge bills of which he spoke—up to £2,000 a month. The strain and financial burden of that is all on the families. Surely that is not how any of us in this place anticipated it would be or wanted it to be.

When the then Home Secretary agreed that medicinal cannabis would be legal for use in the United Kingdom, I think we all believed that parents would no longer be forced to watch their children suffer, knowing that a treatment was available. What has happened since is heartbreaking. In the intervening years, they have been forced to source medication themselves, sometimes travel abroad—again at huge cost—to collect it, challenge the medical authorities and face rejection and repeated appeals for NHS prescriptions.

Surely no one in this place wants even to contemplate what it would mean to have a loved one—husband, wife, partner, brother, sister, friend or child—who had to pay for the medication they needed simply to go on with day-to-day life. Think of the diabetic without insulin or the asthmatic without an inhaler; this is no different, but it is new. With so much red tape and inflexible guidelines, too many people face being left alone, helpless and simply unable to afford life-changing treatment. In fact, since November 2018, just three NHS prescriptions have been issued for the type of medicinal cannabis that is life-transforming for these children.

Clearly, guidelines are not empowering medical professionals to do the job they want to do and provide the best possible care for their patients, knowing that they have the establishment’s support. Critics often point to the National Institute for Health and Care Excellence and say it has restricted medicinal cannabis, but only a few months ago it said that there was no ban and that prescriptions should be done on a case-by-case basis. Still parents are told that the medical profession does not have the confidence to prescribe the medication because of a lack of evidence and that clinical randomised control trials are needed. However, that will not work, because this medication does not come in a standard dosage and the balance of ingredients needs to be changed to suit individual patients. Even if medical trials did work, they would be of no use to those children who are already benefiting from medicinal cannabis. Trials would be both unethical and unsafe, because those children would have to stop taking the medicine that is working for them, perhaps for a placebo, and risk a return of life-threatening seizures.

[Christine Jardine]

I could not agree more. We must address that quickly. As the hon. Gentleman said, it should not be mixed up with the scenarios he described; it is often children—adults as well—on a carefully prescribed medication that the Government have supported.

There is also the argument of there being no evidence because of the lack of clinical trials. Well, there is an abundance of observed evidence that medicinal cannabis works, so the clinical trials explanation falls short. There are also those who point to the medicine Epidiolex being available on prescription for two rare forms of childhood epilepsy, but I understand that that is less effective for many sufferers. Scientists say that the medicinal cannabis that these children need is effective for 95% of children.

[Alberto Costa]

I thank the hon. Member for giving way for a second time. On that point, one thing I have discovered in the debate is the lack of confidence in the medical profession. In fairness to the Government, they do not have a role at all in enforcing the medical profession’s prescription of medication. Does she agree that the medical profession ought to listen to her and others in the House tonight, put its shoulder to the wheel and encourage its members to listen to the science and help those children across the country who need the medication badly?

[Christine Jardine]

The hon. Member makes exactly the point that I would make. I think we all appreciate that the Government do not have the power to make the medical profession do anything, but they can be encouraged to put their shoulder to the wheel and get behind this cause.

--- Later in debate ---

[Sir Mike Penning]

I alluded earlier to the narrow-mindedness of people who have taken an oath to protect people and protect children. No one, I would have thought, goes into the medical profession to hurt people, but at the end of the day, we have a group of children—not thousands, but a small group—whose parents are crying out, “Please listen to my specialist. Please listen to me, as a parent trying to save my child’s life.”

[Alberto Costa]

I thank my right hon. Friend for the good work that he did as my predecessor on the APPG. Does he agree that, given that there is such a small number of children across the country who suffer from severe forms of epilepsy, a temporary measure would be for the Government to be bold and simply cover the cost of private prescriptions until we develop the proper framework, along with the science that demonstrates conclusively the efficacy of this medicine?

[Sir Mike Penning]

I could not agree with my hon. Friend more strongly. That was what we did in the Home Office, which is why Alfie and some of the other children got their prescriptions paid for by the NHS. We set the committee up and we did it. I say again that I feel personally guilty, because we worked in all good faith to get the issue across to the Department of Health and it still has it, and those parents feel guilty, because they feel that other children should be having the benefits that Alfie is getting.

Surely, given the will of this House, the will of the Government, the will of previous Prime Ministers, the cross-party support, the fact that the previous Health Secretary came and met the parents here in the House and made them a commitment, and the fact that the Home Secretary who changed the legislation is now the Health Secretary, it must be a no-brainer. Let us look after these kids.

--- Later in debate ---

[Jo Churchill]

It is not in my gift to take that option, but I will take that comment back to the Health Secretary and have further discussions. As I said, in our very first meeting he highlighted this as an area where he wanted to see movement, and we are determined to get some movement.

We need the evidence base and we need trials to be ongoing to help inform future commissioning decisions. NHS England has also established a patient registry to collect uniform outcome data from licensed and unlicensed products. The refractory epilepsy specialist clinical advisory service has been established to provide expert impartial advice for clinicians treating complex cases while we await the outcome of clinical trials.

I hope I have managed to convey how committed I am, because I do believe that we ought to be able to find the solution for these children, and I was very aware of the hon. Lady’s point about what happens when they reach adulthood. My right hon. Friend the Member for Hemel Hempstead has spoken to me about the fact that as children move through and medicines gets better they thankfully survive longer, but then we have the added complexity of having to look at the system, which is why we want to make sure we find a solution. Finding the right solution is what we are after, because it will take time to generate further evidence and see the results of clinical trials. I do understand, however, that patients and families continue to access these medicines privately, and that the cost of doing so is very high. There are no easy or quick solutions, but I am committed that the Department will reconsider what action the Government may reasonably take with regard to access to unlicensed cannabis-based products for medicinal use where clinically appropriate.

The health of the children and adults dealing so courageously with these difficult-to-treat conditions is of paramount importance. I think it was Hannah who said to me that for every time Alfie does not end up in hospital having fitted repeatedly, there is a saving to the system.

[Alberto Costa]

Will my hon. Friend give way on that point?

[Jo Churchill]

Yes, finally, but then I am going to conclude.

[Alberto Costa]

My right hon. Friend the Member for Hemel Hempstead (Sir Mike Penning) made the point that the Government did supply the medication from a different Department, at no cost to the parents. I have suggested to the Minister that the Government, only on a temporary basis, should cover the cost for the very small number of children across the country who desperately need this medication, which they obtain through private prescription. Can she commit today from the Dispatch Box that she will at least try her best to find the money from her Department to cover those costs on a temporary basis?

[Jo Churchill]

I hope that I outlined earlier that a mixture of solutions is needed to crack this problem. We are not taking anything off the table. We are looking at every option that we can to ensure that we get the right support. Health is devolved, and the access to and funding of medicines is a matter for the relevant devolved nation. I hope, however, that hon. Members have seen that we are all trying to work on the challenge together, because there should not be a difference. As people have said this evening, this is not partisan; it is about making sure that we get the right care to the children.

I will commit that the health of children and adults is of paramount importance. It is of paramount importance to the Secretary of State and to me. I can assure hon. Members that I will carry on making sure, with my team, that we are doing as much as we can to try to get us to a solution that helps these children in the short term but also the long term, while having as the second strand of work the evidence base that we need to support the wider prescribing of any drug, because we need to make sure that we are doing it with care.

Question put and agreed to.

Covid-19 Update

Alberto Costa Excerpts

Monday 28th June 2021 Commons Chamber

[Sajid Javid]

I thank the hon. Lady for her comments about working together. She is absolutely right to say that, especially on something as important as social care, which she is right to raise as a priority for the Government and for this House. She reminded the House that, sadly, so many people in care homes have lost their lives through this pandemic. She will be aware that, even before the pandemic, the Government had pumped billions more into the social care system, and during the pandemic there was a lot of support, but a lot more needs to be done, and I think that is what she rightly gets to. The Government have said that the best way to find a sustainable solution to the country’s social care challenge is for parties to work together and co-operate, and I would happily meet her.

[Alberto Costa (South Leicestershire) (Con) [V]]

I welcome my right hon. Friend back to the Government, and I look forward to working with him in the months and years ahead.

The Feilding Palmer Hospital in Lutterworth is the only hospital in my constituency. It was threatened with closure but is now being used as the principal covid vaccination centre in the southern part of my South Leicestershire constituency. Once the Secretary of State has settled into his important role, will he meet me to discuss the important future that I hope to see for that much-valued district hospital?

[Sajid Javid]

I thank my hon. Friend for raising that issue about his local hospital. As a constituency MP, I absolutely understand the importance of local hospitals and having that support in the local community. This hospital in particular has done a great job with vaccinations, and it continues to do a fantastic job. I think that is a very good sign of the contribution that it can potentially continue to make for the local community, and I would very happily meet him.

Oral Answers to Questions

Alberto Costa Excerpts

Tuesday 12th January 2021 Commons Chamber

[Alberto Costa (South Leicestershire) (Con)]

If he will take steps to ensure that Feilding Palmer Community Hospital in Lutterworth is reopened as a covid-19 vaccination centre.

[The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)]

Across the United Kingdom we have more than 2,700 vaccination sites up and running, with seven vaccination centres opening this week and more to come next week and the week after. Regarding the question about Feilding Palmer hospital that my hon. Friend has raised, I can confirm that this site is now being actively considered as a vaccination hub.

[Alberto Costa [V]]

I thank the Minister and his team for the help that they gave me and my team in cajoling, pushing and encouraging the clinical commissioning group to reopen the Feilding Palmer hospital in Lutterworth as a vaccination centre; that is excellent news for the people of Lutterworth and the surrounding villages.

Will the Minister also confirm that the remaining parts of south Leicestershire, from Broughton Astley to Braunstone, from Thorpe Astley to Arnesby, will also be able to access vaccination centres locally?

[Nadhim Zahawi]

I am grateful to my hon. Friend not just for his characteristic support and encouragement, but for his championing of his constituents. I can confirm, as the Secretary of State has said, that all his constituents will be no more than 10 miles away from a vaccination centre, and I am pleased that the Sturdee Road health and wellbeing centre, which is a little over 10 miles away from Lutterworth, is administering vaccines now.

Public Health

Alberto Costa Excerpts

Wednesday 6th January 2021 Commons Chamber

[Alberto Costa (South Leicestershire) (Con) [V]]

None of us wishes to pass such restrictions on all our freedoms. We are a parliamentary democracy that cherishes freedom, but here we are about to pass draconian restrictions on our personal liberties.

Our job must be to encourage, cajole and demand of the Government that they do everything in their power for the vaccines to be manufactured, distributed and offered to our fellow citizens as soon as possible. Ministers are working at breakneck speed. I pay tribute to the Secretary of State, his fellow Ministers, senior civil servants in central Government who are managing the vaccination programme, and all the other public stakeholders—the NHS, doctors, nurses—organisations and individuals who are helping to distribute the vaccines as quickly as possible. The more vaccination centres we have properly staffed and resourced with vaccines, the quicker we can vaccinate our constituents, and thus the quicker we can consider lifting these draconian regulations.

Turning to South Leicestershire, yesterday I met the chief executive officer of the local clinical commissioning group, Andy Williams, along with his colleagues from the Leicestershire Partnership NHS Trust and Lutterworth GPs. I thank him for meeting me at such short notice. I have been reassured by him and his team that they are working to ensure that my constituents are offered the opportunity of receiving the vaccine in Lutterworth, Blaby and across South Leicestershire.

I know that the House will want to pay tribute to NHS stakeholders such as Andy Williams and the CCG for all the work they are doing to open vaccination centres wherever possible in each of our constituencies across the country. I impressed on Andy Williams that the decision we are about to take today as legislators of the sovereign British Parliament in restricting freedoms and, in effect, closing down large parts of our economy and our education centres can be lifted only when he and his NHS colleagues succeed in their logistical organisation of opening and operating vaccination centres. It is right that we scrutinise the work of the CCGs across our country and all related NHS and other stakeholders involved in this mammoth task. I will be supporting the Government today, but only under the clear understanding that they are doing all they can to obtain vaccines and distribute them quickly to all our constituents.

Local Contact Tracing

Alberto Costa Excerpts

Wednesday 14th October 2020 Commons Chamber

[Rachel Reeves]

My hon. Friend makes his point well. He has been a staunch advocate of transparency and value for money in the delivery of public services. The Government’s own Minister in the Cabinet Office in the other place has made those points as well, saying that the Government are spending too much money on consultants when that work could be done in-house with better value for taxpayers. I very much agree with my hon. Friend’s comments.

The minutes of the Scientific Advisory Group for Emergencies meeting from three weeks ago on 21 September, as well as suggesting a circuit break to deal with the rising infection numbers, reflected on the performance of the Government’s approach to test, trace and isolate. The minutes said that

“relatively low levels of engagement with the system…coupled with testing delays…is having a marginal impact on transmission”.

All that money spent, yet this key part of the Government’s system to keep us safe is only having a marginal impact on transmission.

[Alberto Costa (South Leicestershire) (Con)]

Does the hon. Lady not accept that this is a unique situation? This is one of the worst crises that this country has ever faced, and I invite her to assist the Government, rather than constantly opposing every measure that the Government are taking in what is an extremely challenging situation.

[Rachel Reeves]

That is exactly why I am urging the Government to use the local expertise we have in all our local authorities around the country. We should not reinvent the wheel, but use that local expertise, rather than wasting hundreds of millions of pounds of taxpayers’ money.

The Prime Minister promised a world-beating test and trace system, yet we have one that is barely functioning. We have a system that is now so broken that SAGE is saying it is making next to no difference. We are all paying the price for these terrible mistakes. The truth is that as soon as the Government looked to a privatised solution, a political choice was made about how to respond to a public health crisis.

Serco is not integrated into the fabric of any of our communities. Ministers could have spoken to the Local Government Association. They could have spoken to the Association of Directors of Public Health. Instead, they chose to speak to Serco. There is a cosiness between the Conservative Government and these outsourcing companies, despite their failures to deliver.

Let us look at Serco’s record. Last year, Serco was fined £23 million as part of a settlement with the Serious Fraud Office over electronic tagging contracts. In December, two former senior executives at Serco were charged for that offence. In 2018, Serco was fined £2.8 million after it was revealed that it was providing asylum seekers with squalid, unsafe slum housing.

One would think that whenever Serco bids for a contract, sirens would be going off all over Whitehall, except that Serco did not bid for the contact tracing contract. It was handed it on a plate, with no competition, no rigour and no transparency. Ministers may claim that it is a coincidence that hundreds of millions of pounds of public contracts have been awarded to companies with clear links to the Conservative party, including Serco. That would be a heck of a coincidence, wouldn’t it?

Covid-19 Update

Alberto Costa Excerpts

Monday 29th June 2020 Commons Chamber

[Alberto Costa (South Leicestershire) (Con)]

Thank you, Mr Speaker, for calling me as the MP for South Leicestershire, an area directly impacted by my right hon. Friend’s statement this evening. Will the Secretary of State confirm that the funding that he has promised Leicestershire County Council and Leicester city will also be split to include the affected district councils such as Blaby District Council? Will he also explain what the impact will be for areas outside the city of Leicester? He keeps mentioning Leicester, but what areas in Leicestershire will be impacted by his statement?

[Matt Hancock]

Yes, absolutely; we will be publishing imminently the exact details of which wards are included in these measures. That decision is being taken by Leicestershire County Council along with PHE. I understand the call for financial support for district and borough councils as well as for the county council. In the first instance, that funding will flow through the county council, but I will absolutely look at the point my hon. Friend has raised.

Cystic Fibrosis Drugs: Orkambi

Alberto Costa Excerpts

Monday 10th June 2019 Westminster Hall

[Paul Scully (Sutton and Cheam) (Con)]

I beg to move,

That this House has considered e-petition 231602 relating to access to Orkambi and other drugs for people with cystic fibrosis.

It is a pleasure to serve under your chairmanship, Mr Bailey. I will read the petition, if I may:

“Children & young adults with CF endure lifelong suffering & early death. They need Orkambi and other precision medicines as they are developed. Sufferers in the EU, US & Australia can access the drugs, but not the UK. Hundreds have died in the 3 years since these drugs were licensed. All MPs who debated the petition in March were passionately in favour of supplying the drugs. Despite an ever-increasing abundance of evidence as to the drugs’ effectiveness, CF sufferers still do not have access. Case studies report miraculous improvements in health. Consultants nationwide have asked the NHS to make the drugs available. Doctors have expressed distress at seeing children die whilst the drug they need is on the shelf. After 3 years, conclude negotiations and fund these drugs.”

I pay tribute to Catherine Meredith, who started the petition, and the 108,144 people who had signed it as of this morning. Many hon. Members present are here because of their constituents and their long-lasting championing of cystic fibrosis treatment and the need to get these drugs to market as soon as possible.

Cystic fibrosis is a severe, devastating and progressive disease. It is a genetic disease, so we know the exact number of people living with it—70,000 around the world. It is considered by many to be a Celtic disease; the UK has 12% of all sufferers, which makes it an important place for research and an important market for pharmaceutical companies, such as Vertex, that have been working on treatment.

[Alberto Costa (South Leicestershire) (Con)]

I congratulate my hon. Friend on securing a clearly important debate. If Orkambi were available on the NHS, my constituent Amelie-Rose Sullivan, who is only two years old, would be able to take that life-saving medicine. Having spoken with her family, I understand that she has needed antibiotics on five occasions, which involves a two-week course each time—a cost to the NHS. Antibiotics might not have been needed if she were taking Orkambi, which underlines the need for Orkambi to be available. Ultimately, it would be better value for the taxpayer and our constituents.

[Paul Scully]

My hon. Friend is absolutely right. Before I led a similar debate for the Petitions Committee roughly this time last year, I went to the Cystic Fibrosis Trust, as I did this morning, where I met and spoke to a lot of parents whose children are suffering, as he has mentioned. This morning, I met a number of adult sufferers, who I will speak further about in a minute. One of them, who is 43, described the disease—this is harsh, especially for any sufferers watching—as his lungs filling up and effectively drowning. That is pertinent to me, because my father died of mesothelioma 30 years ago, after a year of suffering. This man is 43; I cannot imagine that suffering. Early treatment for children, however, stops that build-up in the first place and allows them to keep their lung capacity higher for longer, so they can have a proper standard of living.